|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ovarian cancer standard of care: are there real alternatives?显示文摘Ovarian cancer remains a major issue for gynecological oncologists, and most patients are diagnosed when the disease is already advanced with a poor chance of survival. Debulking surgery followed by platinum-taxane chemotherapy is the current standard of care, but based on several different strategies currently under evaluation, some encouraging data have been published in the last 4 to 5 years. This review provides a state-of-the-art overview of the available alternatives to conventional treatment and the most promising new combinations. For example, neoadjuvant chemotherapy does not seem to be inferior to primary debulking. Despite its outcome improvements, intraperitoneal chemotherapy struggles for acceptance due to the heavy toxicity. Dose-dense chemotherapy, after showing an impressive efficacy in Asian populations, has not produced equal results in a European cohort, and the results of alternative platinum doublets are not superior to those of carboplatin and paclitaxel. In this setting, adherence to a maintenance therapy after first-line treatment and multiple(primarily antiangiogenic) agents appears to be effective. Although many questions, including the duration of maintenance treatment and the use of bevacizumab beyond progression, remain unanswered, new biologic agents, such as poly(ADP-ribose) polymerase(PARP) inhibitors, nintedanib, and mitogen-activated protein/extracellular signal-regulated kinase(MEK) inhibitors, have emerged as potential therapeutic options in the very near future. Based on the multiplicity of available strategies, the histological and molecular features of the tumor, in addition to patient's clinical condition and disease state, continue to gain importance in guiding treatment choices. | Chiara Della Pepa Giuseppe Tonini Carmela Pisano Marilena Di Napoli Sabrina Chiara Cecere Rosa Tambaro Gaetano Facchini Sando Pignata | 2015 | Chinese Journal of Cancer2015，34，1： | 5 |
| 2 | Target Therapies in Pancreatic Carcinoma显示文摘 | Nicola Silvestris Antonio Gnoni Anna Elisabetta Brunetti Leonardo Vincenti Daniele Santini Giuseppe Tonini Francesca Merchionne Evaristo Maiello Vito Lorusso Patrizia Nardulli Amalia Azzariti Michele Reni | 2014 | Current Medicinal Chemistry2014，，8： | 2 |
| 3 | Subagging for credit scoring models 显示文摘 | GIUSEPPE PALEOLOGO ANDRe ELISSEEFF GIANLUCA AN- TONINI | 2010 | European Jour- nal of Operational Research2010，，201： | 1 |
| 4 | Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study显示文摘 | Daniele Santini Bruno Vincenzi Gaia Schiavon Marisa Di Seri Vladimir Virzí Bruno Spalletta Marco Caricato Roberto Coppola Giuseppe Tonini | 2007 | Cancer Chemotherapy and Pharmacology2007，，5： | 1 |
| 5 | Pharmacogenomics of cetuximab in metastatic colorectal carcinoma显示文摘 | Nicola Silvestris Bruno Vincenzi Anna Elisabetta Brunetti Fotious Loupakis Emanuela Dell’Aquila Antonio Russo Mario Scartozzi Riccardo Giampieri Stefano Cascinu Vito Lorusso Giuseppe Tonini Alfredo Falcone Daniele Santini | 2014 | Pharmacogenomics2014，，13： | 1 |
| 6 | In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients显示文摘 | Daniele Santini Federico Martini Maria Elisabetta Fratto Sara Galluzzo Bruno Vincenzi Chiara Agrati Federica Turchi Paola Piacentini Laura Rocci John S. Manavalan Giuseppe Tonini Fabrizio Poccia | 2009 | Cancer Immunology Immunotherapy2009，，1： | 1 |
| 7 | Interleukin 1β-511T gene (IL1β) polymorphism is correlated with gastriccancer in the Caucasian population: Results from a meta-analysis显示文摘 | Bruno Vincenzi Giuseppe Patti Sara Galluzzo Francesco Pantano Olga Venditti Daniele Santini Annamaria Ruzzo Gaia Schiavon Michele Caraglia Monica Marra Francesco Graziano Giuseppe Tonini | 2008 | Oncology Reports2008，，5： | 1 |
| 8 | Prolonged Survival After Extracranial Metastasectomy From Synchronous Resectable Lung Cancer显示文摘 | Vincenzo Ambrogi MD Giuseppe Tonini MD Tommaso Claudio Mineo MD | 2001 | Annals of Surgical Oncology2001，，8： | 1 |
| 9 | Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status显示文摘 | Lorenzo Fornaro Giacomo Giulio Baldi Gianluca Masi Giacomo Allegrini Fotios Loupakis Enrico Vasile Samanta Cupini Irene Stasi Lisa Salvatore Chiara Cremolini Bruno Vincenzi Daniele Santini Giuseppe Tonini Francesco Graziano Annamaria Ruzzo Emanuele Canest | 2010 | Critical Reviews in Oncology and Hematology2010，，3： | 1 |
| 10 | Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial显示文摘 | Stefano Cascinu Rossana Berardi Roberto Labianca Salvatore Siena Alfredo Falcone Enrico Aitini Sandro Barni Francesco Di Costanzo Elisa Dapretto Giuseppe Tonini Chiara Pierantoni Salvatore Artale Silvia Rota Irene Floriani Mario Scartozzi Alberto Zaniboni | 2008 | Lancet Oncology2008，，1： | 1 |
| 11 | Liver involvement in the course of thymoma-associated multiorgan autoimmunity:The first histological description显示文摘To the Editor:Thymoma-associated multiorgan autoimmunity(TAMA)is a rare paraneoplastic syndrome described in patients with thymoma and characterized by multiorgan failure and graft-versus-host dis-ease(GVHD)like pathology affecting the skin,the gastrointestinal tract,and the liver.To date,only 21 cases are reported in liter-ature[1],with some patients presenting gastrointestinal and hep-atic manifestations,mainly colitis,diarrhea,and abnormal liver en-zymes,but the hepatic involvement has not been histologically characterized yet. | Fabrizio Citarella Umberto Vespasiani-Gentilucci Anna Crescenzi Antonella Bianchi Vladimir Virzì Giuseppe Tonini | 2022 | Hepatobiliary & Pancreatic Diseases International2022，21，1： | 0 |
| 12 | Target therapy in gastrointestinal tract sarcoma:What is new?显示文摘Soft tissue sarcoma are rare tumors arising mostly from embryonic mesoderm, that can affect almost any part of the human body, including the gastrointestinal tract. The prognosis associated with soft tissue sarcoma is still poor, mainly because of the low efficacy of traditional approaches based on surgery and chemotherapy. As a result of genetic and molecular analysis, several new target therapies have been developed, leading to a significant improvement in the survival of patients affected by advanced disease. In this review we aim to explore the therapeutic potential and benefit of target therapy in the management of gastrointestinal soft tissue sarcoma and the possible complications or pitfalls of such an approach. | Bruno Vincenzi Anna Maria Frezza Daniele Santini Giuseppe Tonini | 2010 | World Journal of Gastrointestinal Oncology2010，2，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员